Table 1 Effects of different clinicopathological factors on the survival of patients with combined hepatocellular and cholangiocellular carcinoma after liver transplantation
Prognostic factors | Cases (%) | Mean survival time (month) | P-value |
|---|---|---|---|
Age | |||
<50-year | 7 (33%) | 50.8 ± 18.1 | 0.899 |
≥50-year | 14 (67%) | 45.0 ± 11.8 | |
Preoperative treatment | |||
None | 13 (62%) | 46.7 ± 12.3 | 0.769 |
TACE, RFA, or chemotherapy | 8 (38%) | 49.0 ± 14.1 | |
Preoperative AFP | |||
<20 ng/mL | 8 (38%) | 44.0 ± 17.2 | 0.898 |
≥20 ng/mL | 13 (62%) | 37.1 ± 9.5 | |
Preoperative CA19-9 | |||
<37U/mL | 9 (43%) | 53.6 ± 15.8 | 0.268 |
≥37U/mL | 12 (57%) | 48.8 ± 8.9 | |
Child-Pugh Grading | |||
Grade A | 16 (76%) | 47.3 ± 13.1 | 0.347 |
Grade B | 3 (14%) | 39.1 ± 9.1 | |
Grade C | 2 (10%) | 53.6 ± 12.0 | |
Cirrhosis* | |||
No | 3 (14%) | 9.0 ± 1.0 | 0.031 |
Yes | 18 (86%) | 52.8 ± 11.1 | |
Tumor distribution | |||
Right lobe | 12 (57%) | 53.5 ± 12.9 | 0.265 |
Double lobes | 9 (43%) | 41.3 ± 10.2 | |
Cumulative tumor diameter* | |||
≤5 cm | 4 (19%) | 83.5 ± 16.9 | 0.047 |
5–10 cm | 7 (33%) | 32.8 ± 10.1 | |
>10 cm | 10 (48%) | 17.7 ± 4.0 | |
Tumor quantity | |||
Singular | 5 (24%) | 37.3 ± 19.2 | 0.084 |
2–3 | 8 (38%) | 50.3 ± 14.8 | |
≥4 | 8 (38%) | 34.3 ± 13.0 | |
Lymph node metastasis* | |||
Yes | 5 (24%) | 14.0 ± 6.1 | 0.039 |
No | 16 (76%) | 54.7 ± 11.7 | |
HCC differentiation | |||
Intermediate to well differentiated | 16 (76%) | 54.3 ± 15.2 | 0.074 |
Poorly differentiated | 5 (24%) | 45.6 ± 12.1 | |
CC differentiation | |||
Intermediate to well differentiated | 12 (57%) | 56.7 ± 9.3 | 0.083 |
Poorly differentiated | 9 (43%) | 41.0 ± 13.8 | |
Macroscopic thrombosis* | |||
Yes | 8 (38%) | 21.0 ± 5.1 | 0.028 |
No | 13 (62%) | 57.9 ± 13.1 | |
Microvascular thrombosis | |||
Yes | 14 (67%) | 42.5 ± 12.5 | 0.226 |
No | 7 (33%) | 58.8 ± 14.9 | |
Allen typing* | |||
Separation/collision | 15 (71%) | 47.9 ± 9.9 | 0.037 |
Mixed | 6 (29%) | 21.3 ± 14.2 |